Indications
Relief of migraine attacks (with or without aura).
$13.00
Active ingredient: | |
---|---|
Dosage form: |
Relief of migraine attacks (with or without aura).
Inside (the tablet is swallowed whole, washed down with water).
The initial single dose is 50 mg, if necessary, the dose can be increased to 100 mg.
If the symptoms of migraine do not disappear and do not decrease after taking the first dose, then taking a second dose to stop the ongoing attack is not prescribed.
To stop subsequent attacks (if symptoms decrease or disappear, and then resume), you can take a second dose within the next 24 hours, provided that the interval between doses is at least 2 hours.
The maximum daily dose when taken orally is 300 mg.
With caution:
Each film-coated tablet contains sumatriptan succinate 70 mg or 140 mg (based on sumatriptan 50 mg and 100 mg).
Excipients: lactose (milk sugar), calcium hydrophosphate (calcium phosphate di-substituted), magnesium stearate, povidone.
Excipients for the shell: hypromellose (hydroxypropyl-methylcellulose), copovidone (copolividone), polyethylene glycol 6000 (macrogol), talc, titanium dioxide, red dye [Ponceau 4R].
Each film-coated tablet contains sumatriptan succinate 70 mg or 140 mg (based on sumatriptan 50 mg and 100 mg). Excipients: lactose (milk sugar), calcium hydrophosphate (calcium phosphate di-substituted), magnesium stearate, povidone. Excipients for the shell: hypromellose (hydroxypropyl-methylcellulose), copovidone (copolividone), polyethylene glycol 6000 (macrogol), talc, titanium dioxide, red dye [Ponceau 4R].
Pharmacological group: Â Anti-migraine medication.
ATX code: Â N02CC01.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics umatriptan is a specific selective agonist of vascular 5-hydroxytryptamine-1 receptors (5 HT 1D), does not affect other subtypes of 5 HT serotonin receptors (5 HT 2-5 HT 7).
5 HT 1D receptors are located mainly in the blood vessels of the brain, and their stimulation leads to narrowing of these vessels. Reduces the sensitivity of the trigeminal nerve. Both of these effects may underlie the antimigrenous effect of sumatriptan. The clinical effect is usually observed 30 minutes after oral use of the drug.
Pharmacokineticsafter oral use, sumatriptan is rapidly absorbed,70% of the maximum plasma concentration is reached in 45 minutes. After taking 100 mg, the maximum concentration in blood plasma is on average 54 mg / ml. Bioavailability is 14% due to intensive presystemic metabolism and incomplete absorption. The association with plasma proteins is low (14-21%).
Sumatriptan is metabolized by monoamine oxidase A. The main metabolite, the indoleacetic analog of sumatriptan, is mainly excreted in the urine as a free acid and a glucuronide conjugate. This metabolite has no activity against 5HT1-and 5 HT2-serotonin receptors.
Relief of migraine attacks (with or without aura).
With caution:
the incidence of side effects is classified according to the recommendations of the world health organization: very often – at least 10%; often – not less than 1% but < 10%; infrequently – no more than 0.1% but < 1%; rarely – not less than 0.01%, but less than 0.1%; very rarely – less than 0.01% (including isolated cases).
From the cardiovascular system: very rarely – bradycardia, tachycardia, arrhythmia, transient increase in blood pressure (BP) (immediately after the start of treatment), transient signs of myocardial ischemia on the electrocardiogram, spasm of coronary vessels, myocardial infarction, Raynaud’s syndrome, decreased blood pressure, “flushes” of blood to the face.
From the respiratory system: often-shortness of breath, temporary irritation of the mucous membrane or a burning sensation in the nasal cavity or throat.
From the digestive system: often – nausea, vomiting; slight increase in the activity of “liver” enzymes; very rarely-ischemic colitis, diarrhea, abdominal discomfort.
Nervous system disorders: Â often – dizziness, drowsiness, sensitivity disorders, including paresthesia, hypesthesia; very rarely-convulsions (usually with a history of convulsions); unknown frequency-tremor, dystonia, anxiety.
From the side of the visual organ: infrequently-diplopia, flickering of “flies” in front of the eyes, nystagmus, scotoma, decreased visual acuity; very rarely-partial temporary loss of vision (keep in mind that visual disturbances may be associated with the migraine attack itself).
From the musculoskeletal system: often-myalgia; unknown frequency-rigidity of the occipital muscles, arthralgia.
Allergic reactions: very rare – skin rash, urticaria, pruritus, erythema, anaphylaxis.
Other: often-pain, tingling, feeling hot, feeling weak and / or tired, nosebleeds, tightness or heaviness (these symptoms are usually transient, but can be intense and occur in any part of the body, including the chest and neck); unknown frequency – increased sweating.
Prolonged vasospasm is possible when administered concomitantly with ergotamine and ergotamine-containing drugs.
It is possible to reduce the intensity of sumatriptan metabolism, increase its concentration, with interaction between sumatriptan and MAO inhibitors.
With the simultaneous use of sumatriptan and drugs from the group of selective serotonin reuptake inhibitors, weakness, hyperreflexia and impaired coordination of movements may develop.
No interactions of sumatriptan with propranolol, flunirizine, pisotifen, or ethanol were observed.
Inside (the tablet is swallowed whole, washed down with water).
The initial single dose is 50 mg, if necessary, the dose can be increased to 100 mg.
If the symptoms of migraine do not disappear and do not decrease after taking the first dose, then taking a second dose to stop the ongoing attack is not prescribed.
To stop subsequent attacks (if symptoms decrease or disappear, and then resume), you can take a second dose within the next 24 hours, provided that the interval between doses is at least 2 hours.
The maximum daily dose when taken orally is 300 mg.
A single subcutaneous dose of 12 mg of sumatriptan did not cause any side effects.
When administered subcutaneously at a dose of more than 16 mg or when taken orally at a dose of more than 400 mg, sumatriptan did not cause any unforeseen side effects, in addition to those listed above.
Treatment: gastric lavage, taking activated charcoal, monitoring the condition of patients for at least 10 hours, if necessary – symptomatic therapy.
Sumatriptan is not intended for the prevention of migraines.
Sumatriptan should only be taken if the diagnosis of migraine is clear.
Sumatriptan should be used as early as possible after the onset of a migraine attack, but the drug is equally effective at any stage of the attack. If there is no effect from the first dose, the diagnosis should be clarified.
Patients at risk from the cardiovascular system should not start therapy without a preliminary examination (women in the postmenopausal period, men over the age of 40, people with risk factors for CHD).
Before prescribing sumatriptan to patients with newly diagnosed or atypical migraines, other potentially dangerous neurological diseases should be excluded.
After taking sumatriptan, there may be pain and a feeling of tightness in the chest. The pain may be intense and radiate to the neck. If there is reason to believe that these symptoms are a manifestation of CHD, it is necessary to conduct an appropriate examination.
Impact on the ability to drive vehicles and manage vehicles
With migraines, as well as against the background of sumatriptan therapy, drowsiness may develop. Therefore, during the use of sumatriptan, care should be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.
Sumatriptan. Film-coated tablets
At a temperature not exceeding 25° C, in a dry place protected from light and out of reach of children.
life is 2 years.
Sumatriptan
By prescription
Tablets
Reviews
There are no reviews yet